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ngagement of integrin receptors with the extracellular
matrix induces the formation of focal adhesions (FAs).
Dynamic regulation of FAs is necessary for cells to
polarize and migrate. Key interactions between FA scaffold-
ing and signaling proteins are dependent on tyrosine
phosphorylation. However, the precise role of tyrosine
phosphorylation in FA development and maturation is
poorly deﬁned. Here, we show that phosphorylation of
type I
 
 
 
 phosphatidylinositol phosphate kinase (PIPKI
 
 
 
661)
on tyrosine 644 (Y644) is critical for its interaction with
E
 
talin, and consequently, localization to FAs. PIPKI
 
 
 
661 is
speciﬁcally phosphorylated on Y644 by Src. Phosphorylation
is regulated by focal adhesion kinase, which enhances the
 
association between PIPKI
 
 
 
661 and Src. The phosphorylation
of Y644 results in an 
 
 
 
15-fold increase in binding afﬁnity
to the talin head domain and blocks 
 
 
 
-integrin binding to
talin. This deﬁnes a novel phosphotyrosine-binding site on
the talin F3 domain and a “molecular switch” for talin
 
binding between PIPKI
 
 
 
661 and 
 
 
 
-integrin that may regulate
dynamic FA turnover.
 
Introduction
 
Integrin binding to the ECM stimulates the formation of
cell–matrix adhesions and mediates the linkage between the
ECM and actin cytoskeleton (for review see Geiger et al.,
2001; Zamir and Geiger, 2001). This linkage is generated by
a submembrane interconnecting complex that consists of
structural proteins such as talin, vinculin, paxillin, 
 
 
 
-actinin,
and tensin, signaling molecules including tyrosine kinases
such as FAK and Src, and serine/threonine kinases, as well
as various adaptor proteins. The molecular complexity of
cell–matrix adhesions enables them to modulate both cell
anchorage and transmembrane signaling (Sastry and Burridge,
2000; Geiger and Bershadsky, 2001). The most common
forms of integrin-mediated cell–matrix adhesions in cultured
cells are termed focal adhesions (FAs), fibrillar adhesions, or
focal complexes, based on their size, shape, and location
within the cell. Signal transduction through FAs has been
implicated in the regulation of a number of key cellular
processes, including growth factor–induced mitogenic signals,
cell survival, cell locomotion and morphogenesis, and tissue
assembly (Burridge and Chrzanowska-Wodnicka, 1996).
The dynamic regulation of FA assembly and disassembly
is the central process for cell motility in response to extracel-
lular stimuli (for review see Parsons et al., 2000). In addition
to regulation by Rho family small GTPases, another key
mechanism for modulation of FA organization and stability
is tyrosine phosphorylation. Nonreceptor tyrosine kinases,
FAK, and Src family kinases are involved in the phosphory-
lation of several FA proteins including paxillin, p130Cas,
tensin, and FAK itself (for review see Cary and Guan, 1999;
Frame et al., 2002). Tyrosine phosphorylation provides
docking sites for additional molecules that contain phospho-
tyrosine (pY)-binding (PTB) domains (for review see Zamir
and Geiger, 2001). Inhibition of tyrosine kinases decreases
the level of intracellular tyrosine phosphorylation and blocks
the development of FAs (for review see Frame et al., 2002).
Consistently, activation of protein tyrosine phosphatases
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disrupts FAs, whereas their inhibition stimulates FA assem-
bly. On the other hand, overactivated Src results in high lev-
els of tyrosine phosphorylation but disruption of FAs (Kellie
et al., 1986), and Src
 
 
 
/
 
 
 
 cells form FAs that fail to turn over
into fibrillar adhesions (Volberg et al., 2001). In addition,
Src family kinases were implicated in regulation of integrin–
cytoskeleton interactions (Felsenfeld et al., 1999). These
data suggest that tyrosine phosphorylation plays an essential
role in the formation and turnover of FAs. However, the ex-
act mechanism underlying tyrosine phosphorylation–medi-
ated modification of the integrin–cytoskeleton linkage and
FA dynamics are still poorly defined.
Phosphatidylinositol 4,5-bisphosphate (PI4,5P
 
2
 
), a lipid
second messenger, modulates FA formation by binding to
vinculin, 
 
 
 
-actinin, and talin facilitating protein–protein in-
teractions and by regulating Rho family small G proteins
(for review see Sechi and Wehland, 2000). The concentra-
tion of PI4,5P
 
2
 
 appears to be regulated locally, enabling
spatial and temporal changes in its availability and sig-
naling. Type I
 
 
 
661 phosphatidylinositol phosphate kinase
(PIPKI
 
 
 
661) targets to FAs and regulates FA assembly by
generating PI4,5P
 
2 
 
and targeting talin to FAs (Di Paolo et
al., 2002; Ling et al., 2002). Our previous data showed that
PIPKI
 
 
 
661 was tyrosine phosphorylated by FAK signaling,
and this enhances PIP kinase activity and correlated with
increased talin association (Ling et al., 2002). Here, we
demonstrate that PIPKI
 
 
 
661 is tyrosine phosphorylated on
Y644 by Src family kinases and is potentially regulated by
FAK signaling. Tyrosine phosphorylation of PIPKI
 
 
 
661 is
required for its strong talin interaction and stable FA tar-
geting. Interestingly, PIPKI
 
 
 
661 tyrosine phosphorylation
strengthens its interaction with talin, effectively competing
with 
 
 
 
1-integrin for binding to talin. The combined data
support a novel mechanism regulating FA dynamics by tyro-
sine phosphorylation and PI4,5P
 
2
 
 signaling.
 
Results
 
FAK signaling mediates the tyrosine phosphorylation 
of PIPKI
 
 
 
661 at Y644
 
Previously, we observed that tyrosine phosphorylation of
PIPKI
 
 
 
661 was dependent on adhesion and FAK signaling
(Ling et al., 2002). Here, we show that PIPKI
 
 
 
661 tyrosine
phosphorylation is dependent on both FAK phosphorylation
on Y397 and FAK activity because neither coexpressed
Y397F nor kinase-dead mutants of FAK induced phosphory-
lation of PIPKI
 
 
 
661 (Fig. 1 A). To map the phosphory-
lation sites, we used the following PIPKI
 
 
 
/
 
 
 
 chimeras:
PIPKI
 
 
 
/
 
 
 
635, PIPKI
 
 
 
/
 
 
 
661, and PIPKI
 
 
 
/
 
 
 
636–661 as
defined in the Materials and methods. We coexpressed the
chimeras with wild-type FAK, and then analyzed their tyro-
sine phosphorylation by immunoprecipitation and immuno-
blotting. Both PIPKI
 
 
 
/
 
 
 
661 and PIPKI
 
 
 
/
 
 
 
636–661 (but
not PIPKI
 
 
 
/
 
 
 
635) were phosphorylated after FAK coexpres-
sion (Fig. 1 B). The COOH-terminal truncation mutants of
PIPKI
 
 
 
661 showed consistent results; PIPKI
 
 
 
661
 
 
 
20
(1–641) was not phosphorylated, PIPKI
 
 
 
661
 
 
 
13 (1–648)
was phosphorylated but to a lesser extent, and PIPKI
 
 
 
661
 
 
 
3
(1–657) was phosphorylated similar to the wild-type kinase
(unpublished data). These data suggest that the major FAK-
mediated phosphorylation sites are in the last 26 amino acids
of PIPKI
 
 
 
661. To define the phosphorylated residues, two Y
to F point mutants were made, Y644F and Y649F (Fig. 1
C). The wild-type or Y to F mutant PIPKI
 
 
 
661 was coex-
pressed in HEK293T cells with wild-type FAK or vector
control, and tyrosine phosphorylation of PIPKI
 
 
 
661 was de-
termined after immunoprecipitation using anti-PIPKI
 
 
 
 anti-
body. As shown in Fig. 1 C, when FAK was overexpressed,
PIPKI
 
 
 
661Y649F was phosphorylated similar to the wild
type. However, PIPKI
 
 
 
661Y644F and PIPKI
 
 
 
661Y644/
649F showed dramatically reduced phosphorylation (Fig. 1
C), suggesting that Y644 is the phosphorylation site down-
stream of FAK signaling.
Figure 1. FAK signaling results in phosphorylation of PIPKI 661 
at Y644. (A) PIPKI 661 was coexpressed with pcDNA3 (control), 
wild-type FAK (FAKwt), Y397F FAK (FAKY397F), or kinase-dead 
FAK (FAKkd) in HEK293T cells as indicated. After 48 h, tyrosine 
phosphorylation of PIPKI 661 was analyzed by immunoprecipitation 
and Western blot as indicated. pY, phosphotyrosine. (B) The epitope-
tagged PIPKI /  chimeras c-Myc-PIPKI / 635 (I /I 635), c-Myc-PIP-
KI / 661 (I /I 661), c-Myc-PIPKI / 636–661 (I /I 636–661), and 
wild-type HA-tagged PIPKI 661 (I 661) were cotransfected with 
pcDNA3 (1) or wild-type FAK (2) in HEK293 cells for 48 h. Tyrosine 
phosphorylation of the PIPKI constructs was examined by immuno-
precipitation and Western blot as indicated. (C) The wild-type (I 661) 
and Y to F mutant (I 661Y644F, I 661Y649F, I 661Y644/649F) 
PIPKI 661 constructs were co-overexpressed in HEK293T cells with 
pcDNA3 (1) or wild-type FAK (2) for 48 h, and tyrosine phosphory-
lation of the PIPKI 661 constructs was examined using immunopre-
cipitation and Western blot as indicated. 
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c-Src directly phosphorylates PIPKI
 
 
 
661 at Y644
 
Src family tyrosine kinases are key factors that associate
with FAK, thereby playing a fundamental role in down-
stream signaling and FAK-regulated processes (Parsons
et al., 2000). Y397 is the autophosphorylation site in
FAK and serves as a Src-binding site. Previous results have
shown that either the Src-binding site (Y397) mutant or a
kinase-dead mutant abrogated FAK’s ability to promote
PIPKI
 
 
 
661 phosphorylation (Fig. 1 A). This suggests that
phosphorylation of PIPKI
 
 
 
661 is mediated by Src or FAK.
To address the role of Src family kinases in PIPKI
 
 
 
661
phosphorylation, Src activity was examined. The Src-spe-
cific inhibitor PP2 (but not the inactive analogue PP3) in-
hibited both basal and FAK-induced tyrosine phosphoryla-
tion of PIPKI
 
 
 
661 (Fig. 2 A), showing that Src family
kinases play an important role in tyrosine phosphorylation
of PIPKI
 
 
 
661. To further explore this possibility, we used
the c-Src, Fyn, and Yes triple knockout cells (SFY
 
 
 
/
 
 
 
) and
c-Src–reintroduced SFY
 
 
 
/
 
 
 
 cells (Src
 
 
 
/
 
 
 
) to analyze the ty-
rosine phosphorylation of endogenous PIPKI
 
 661. As
shown in Fig. 2 B, endogenous PIPKI 661 showed very
low phosphorylation in SFY
 /  cells, whereas reintroduced
c-Src restored PIPKI 661 phosphorylation. Our results in-
dicate that c-Src is directly involved in the tyrosine phos-
phorylation of PIPKI 661, whereas the role of other Src
family kinases members Fyn and Yes need further clarifica-
tion. When the FAK knockout (FAK
 / ) or their parent
(FAK
 / ) cells were examined, the endogenous PIPKI 661
showed similar tyrosine phosphorylation in both cell lines
(Fig. 2 B), indicating that FAK did not phosphorylate
PIPKI 661 directly, but enhanced its phosphorylation via
regulation of Src.
These whole-cell assays were confirmed by in vitro kinase
assays, which demonstrated that c-Src directly phosphory-
lated the His-tagged recombinant PIPKI 661 tail (439–
661; Fig. 2 C), whereas FAK only phosphorylated it very
weakly (unpublished data). Both His-tagged recombinant
PIPKI 661Y644F and PIPKI 661Y644/649F tails were not
efficiently phosphorylated by c-Src in vitro compared with
the wild-type PIPKI 661, whereas the PIPKI Y649F tail
was efficiently phosphorylated (Fig. 2 C). Furthermore, the
phosphopeptide-mapping results confirmed that Y644 is the
major substrate of c-Src because the Y644F mutant failed to
yield two major phosphorylation spots compared with the
wild-type PIPKI 661 map (Fig. 2 D). These results demon-
strate that Y644 is the major tyrosine phosphorylation site of
PIPKI 661 and that Src is the enzyme responsible for
PIPKI 661 phosphorylation.
c-Src associates with PIPKI 661, and this is enhanced 
by FAK
To decipher the mechanism of PIPKI 661 phosphorylation
by Src, we examined whether there was an interaction be-
tween Src and PIPKI 661. HEK293T cells were cotrans-
fected with c-Src and PIPKI 661 for 48 h, harvested, and
PIPKI 661 was immunoprecipitated with purified anti-
PIPKI  antibody. As shown in Fig. 3 A, c-Src was coimmu-
noprecipitated with PIPKI 661. To further explore FAK’s
role in PIPKI 661 phosphorylation, we coexpressed FAK
with c-Src and PIPKI 661. Coexpression of the wild-type
FAK enhanced both tyrosine phosphorylation and Src associ-
ation with PIPKI 661 (Fig. 3 B). FAKY397F, which lacks
the docking site for Src, inhibited the PIPKI 661–c-Src asso-
ciation and failed to increase PIPKI 661 phosphorylation to
Figure 2. c-Src phosphorylates 
PIPKI 661 at Y644. (A) HEK293T cells, 
transfected with PIPKI 661 and the 
indicated constructs, were treated with 
1  M PP2 or PP3 for 30 min at 37 C. 
Then, cells were lysed and tyrosine 
phosphorylation of immunoprecipitated 
PIPKI 661 was examined. (B) 2 mg lysate 
of c-Src/Fyn/Yes triple-knockout (SFY
 / ), 
SFY
 /  cells reintroduced with c-Src 
(Src
 / ), FAK knockout (FAK
 / ), or the 
FAK
 /  parent (FAK
 / ) cells were used 
for immunoprecipitation using purified 
anti-PIPKI  antibody. Then, tyrosine 
phosphorylation of immunoprecipitated 
PIPKI  was analyzed by Western blot as 
indicated. (C) In vitro Src kinase assay with 
His-tagged wild-type (wt-T) or mutant 
(Y644F-T, Y649F-T, or Y644/649F-T) 
PIPKI 661 tails as substrates. Phosphory-
lation data were analyzed using Sigma-
Plot 4.0 from at least three independent 
experiments. (D) Analysis of tyrosine 
phosphorylation by tryptic phosphopep-
tide mapping. In vitro Src kinase assays 
using the substrates described in C were 
resolved by SDS-PAGE, and the tryptic 
digests of the tyrosine-phosphorylated 
substrates were analyzed on two-dimensional maps (exposure for 7 d at  70 C). Arrows indicate the spots corresponding to the loss of 
phosphorylation in the Y644F mutant. The large horizontal arrow points to the cathode and the large vertical arrow indicates the direction of 
chromatographic resolution.1342 The Journal of Cell Biology | Volume 163, Number 6, 2003
the same extant as FAK (Fig. 3 B). This demonstrates that
the interaction of Src with FAK is required for FAK signaling
to enhance Src binding and phosphorylation of PIPKI 661.
Nevertheless, the PIPKI 661 phosphorylation by Src is
not absolutely dependent on FAK because PIPKI 661 can
be phosphorylated in FAK-null cells (Fig. 2 B). In addition,
PIPKI 635 and the PIPKI 661 Y to F mutants coimmuno-
precipitated with c-Src (unpublished data), suggesting that
c-Src association with PIPKI  requires a site distinct from the
last 26 amino acids of PIPKI 661 and independent of phos-
phorylation at Y644 or Y649. In A431 cells, endogenous
PIPKI 661 was tyrosine phosphorylated and associated with
endogenous Src upon cell adhesion to type I collagen (Fig. 3
C). These results indicate that signals initiated from integrin
binding to ligand regulate the Src–PIPKI 661 association,
and consequently, tyrosine phosphorylation of PIPKI 661.
The requirement of integrin-mediated cell adhesion suggests
that FAK regulation is one potential signaling pathway that
modulates the Src–PIPKI  interaction. A431 cells highly
express EGF receptors and, as a result, Src activity could
be greatly enhanced. In other cell lines assayed, including
HEK293T, NRK, and NIH3T3, the interaction between
endogenous PIPKI 661 and Src was more difficult to detect,
although endogenous PIPKI 661 is tyrosine phosphorylated
in these cell lines and is dependent on adhesion on type I
collagen (unpublished data; Ling et al., 2002).
Tyrosine phosphorylation regulates the PIPKI 661–talin 
association and FA targeting of PIPKI 661
Tyrosine phosphorylation of FA proteins regulates cell
spreading and migration by generating protein–protein in-
teraction sites for SH2 and PTB domains (for review see
Figure 3. Src association with PIPKI 661 is enhanced by FAK in 
vivo. (A) 48 h after cotransfection with c-Src and PIPKI 661 constructs, 
HEK293T cells were immunoprecipitated using normal rabbit IgG 
(rIgG) or purified anti-PIPKI  antibody. The immunoprecipitates and 
cell lysate were analyzed by Western blot as indicated. (B) HEK293T 
cells were transfected with PIPKI 661, FAK, and/or Src constructs as 
indicated for 48 h, and then immunoprecipitated using the indicated 
antibodies. Immunoprecipitates were analyzed by Western blot as 
indicated. (C) A431 cells were lifted by trypsin, washed three times, 
and kept in suspension for 1 h at 37 C in serum-free DME. Cells 
were lysed (sus.) or plated on type I collagen-coated (10  g/ml) 
plates in serum-free DME for the indicated time and then lysed, 
immunoprecipitated, and analyzed by Western blot as indicated.
Figure 4. Y644 of PIPKI 661 is required for talin association. 
(A) Immunoprecipitations were performed with HEK293T cell lysate 
with normal rabbit IgG (rIgG), purified anti-PIPKI  antibody, normal 
mouse IgG (mIgG), or monoclonal anti-talin antibody. The immuno-
precipitates were analyzed by Western blot as indicated. (B) Top, 
HEK293T cells were cotransfected with PIPKI 661 and indicated 
FAK construct, and then used for immunoprecipitation with purified 
anti-PIPKI  antibody after 48 h. The immunoprecipitates were 
analyzed by Western blot as indicated. Bottom, quantification of 
talin association. (C) Top, HEK293 cells were transfected with 
wild-type (I 661), last 20 amino acids truncated (I 661 20), last 13 
amino acids truncated (I 661 13), last 3 amino acids truncated 
(I 661 3), or Y to F mutant (I 661Y644F, I 661Y649F, I 661Y644/
649F) PIPKI  constructs for 48 h. Talin association with wild-type or 
mutant PIPKI 661 was examined by immunoprecipitation and 
Western blot as indicated. Bottom, quantification of talin association. 
Data were quantified using NIH image 1.62 and plotted using 
SigmaPlot 4.0 from at least three independent experiments.Tyrosine phosphorylation of PIPKI  | Ling et al. 1343
Panetti, 2002). To further explore the physiological sig-
nificance of PIPKI 661 tyrosine phosphorylation, we
determined if the endogenous PIPKI 661 bound to talin
is tyrosine phosphorylated. Compared with endogenous
PIPKI 661 immunoprecipitated by anti-PIPKI  antibody,
endogenous PIPKI 661 coimmunoprecipitated by anti-
talin antibody had equivalent tyrosine phosphorylation but
less PIPKI 661 (Fig. 4 A), suggesting that PIPKI 661
bound to talin is tyrosine phosphorylated to a greater extent
than free PIPKI 661 in vivo.
Cotransfection experiments also indicated that increased
PIPKI 661 tyrosine phosphorylation, induced by FAK, cor-
relates with an increase in PIPKI 661 bound to talin (Fig. 4
B; Ling et al., 2002). To characterize the role of PIPKI 661
tyrosine phosphorylation, we examined the talin interac-
tion with PIPKI 661 phosphorylation-defective mutants by
coimmunoprecipitation using HEK293T cells. Compared
with the wild-type PIPKI 661, PIPKI 661 20 did not
interact with talin, PIPKI 661 13 had decreased talin as-
sociation, and PIPKI 661 3 maintained identical talin
association (Fig. 4 C). The tyrosine point mutants
PIPKI 661Y644F and PIPKI 661Y644/649F both
showed substantially diminished talin association, whereas
PIPKI Y649F retained talin association comparable with
wild-type PIPKI 661 (Fig. 4 C). These data demonstrate
that tyrosine phosphorylation of the PIPKI 661 COOH
terminus regulates its interaction with talin.
The PIPKI 661–talin association is important for target-
ing PIPKI 661 to FAs (Di Paolo et al., 2002; Ling et al.,
2002). To further explore targeting requirements, FA local-
ization of PIPKI 661 mutants were examined in NRK cells.
Consistent with the ability to interact with talin in coimmu-
noprecipitation experiments, PIPKI 661 20 lost FA target-
ing, PIPKI 661 3 targeted to FAs and colocalized with
talin similar to wild-type PIPKI 661, and PIPKI 661 13
partially retained FA targeting (Fig. 5 A). These data
indicate that in addition to the minimum region
642WVYSPLH
648 for in vitro talin binding (Di Paolo et al.,
2002), in vivo talin association, FA targeting, and phosphor-
ylation of PIPKI 661 also require other residues in the
COOH-terminal 26 amino acids. Consistently, the Y to
F mutants lacking phosphorylation showed reduced talin
association (Fig. 4 C) and lost FA targeting, whereas
PIPKI Y649F localized to FAs similar to its wild-type coun-
terpart (Fig. 5 A). Analysis of 600 cells under each condition
in three independent experiments revealed a correlation with
talin association (Fig. 4 C), FA targeting (Fig. 5 B), and ty-
rosine phosphorylation of PIPKI 661 (Fig. 1 B). Addition-
Figure 5. Tyrosine phosphorylation of PIPKI 661 is required for focal adhesion targeting. (A) NRK cells were transfected with wild-type or 
mutant PIPKI  constructs using FuGENE™ 6 for 24 h. Overexpressed PIPKI  constructs and endogenous talin in NRK cells were visualized by 
anti-PIPKI  antibody (green) and anti-talin antibody (red). Bars, 10  m. (B) Quantification of A. 200 transfected NRK cells were counted per 
slide. Percentage of FA targeting positive cells on each slide were calculated and plotted using SigmaPlot 4.0 from at least three independent 
experiments. (C) Src, Fyn, and Yes triple-knockout cells (SFY
 / ) or c-Src–reintroduced SFY
 /  cells (Src
 / ) were transfected with wild-type 
PIPKI 661 using FuGENE™ 6 for 24 h. Overexpressed PIPKI 661 and pY were visualized by anti-PIPKI  antibody (red) and anti-pY (PY99) 
antibody (green). Bars, 10  m.1344 The Journal of Cell Biology | Volume 163, Number 6, 2003
ally, PIPKI 661 overexpressed in Src
 /  cells showed signif-
icantly greater FA targeting and colocalization with the pY
staining compared with those overexpressed in SFY
 /  cells
(Fig. 5 C). In the FAK
 /  cells, overexpressed PIPKI 661
showed comparable FA targeting as in the parent cells (un-
published data), consistent with results demonstrating that
FAK does not directly phosphorylate PIPKI 661 in vivo.
Together, these data show that c-Src–induced tyrosine phos-
phorylation of PIPKI 661 enhances its FA targeting.
Tyrosine phosphorylation of PIPKI 661 enhances 
talin interaction
To determine whether phenylalanine substitution or loss of
the phosphorylated tyrosine is responsible for the reduced
talin binding of PIPKI 661 mutants, talin interactions were
assessed by GST pull-down using recombinant nonphosphor-
ylated His-PIPKI 661 wild-type or Y to F mutant COOH
terminus and GST-talin head domain. His-PIPKI 661 Y to F
mutants showed identical binding to talin compared with the
wild-type protein (Fig. 6 A), suggesting that the decreased in
vivo talin association resulted from the lack of tyrosine phos-
phorylation and not the phenylalanine substitution.
To address the role of tyrosine phosphorylation, we de-
signed PIPKI 661 peptides containing the talin-binding se-
quence 
642WVYSPLH
648 and flanking sequences, including
normal peptide (PN), Y644-phosphorylated (pY644), Y649-
phosphorylated (pY649), or Y644/Y649 dual-phosphory-
lated (pY644/649) peptides (Fig. 6 B). HEK293T cell ly-
sates were supplemented with these peptides and subse-
quently used for immunoprecipitation. The phosphorylated
peptides inhibited PIPKI 661–talin association much more
efficiently than the nonphosphorylated peptide (Fig. 6 B).
To further explore this, we labeled the PIPKI 661 peptides
with fluorescein at the NH2 terminus and examined their di-
rect binding with purified GST-talin head using fluores-
cence polarization anisotropy. As shown in Fig. 6 C, all of
the phosphorylated peptides showed higher binding affinity
for GST-talin head compared with the nonphosphorylated
peptide. These results demonstrate that PIPKI 661 tyrosine
phosphorylation enhances talin binding.
Phosphorylated PIPKI 661 competes with  1-integrin 
for talin binding
Talin plays a key role in integrin-mediated signaling by link-
ing integrins to the actin cytoskeleton and regulating inte-
grin activation (Liddington and Ginsberg, 2002). The F3
lobe of the band 4.1, ezrin, radixin, moesin homology
(FERM) domain of talin, structurally homologous to a PTB
domain, binds to the  -integrin cytoplasmic tail (Calder-
wood et al., 2002; Garcia-Alvarez et al., 2003) and the last
26 amino acids of PIPKI 661 (Di Paolo et al., 2002; Ling et
al., 2002). Because tyrosine phosphorylation of PIPKI 661
enhanced its interaction with talin, it is important to explore
whether PIPKI 661 would displace  -integrin from talin in
a phosphorylation-dependent manner. We examined the
ability of recombinant PIPKI  proteins or peptides to com-
pete with His- 1-integrin tail for binding to talin in vitro.
His-PIPKI 661 tail, but not His-PIPKI 635 tail, competed
with His- 1-integrin tail in a dose-dependent manner (Fig.
7 A), consistent with the recent report by Barsukov et al.
Figure 6. Tyrosine phosphorylation of PIPKI 661 at Y644 and 
Y649 enhances its interaction with talin. (A) Top, effect of the Y 
to F mutation on PIPKI 661 binding to talin. 50 nM GST talin head 
(GST-TaH) was incubated with indicated amount of His-tagged 
wild-type (I 661T) or mutant PIPKI 661 tails (I 661Y644F-T, 
I 661Y649F-T, or I 661Y644/649F-T). Bottom, bound PIPKI 661 
tail bands were scanned, and the gray scales were quantified by 
NIH image 1.62 and then plotted using SigmaPlot 4.0 from at least 
three independent experiments. (B) Inhibition of PIPKI 661–talin 
interaction by phosphorylated PIPKI 661 peptides. Top, sequences 
and nomenclature of synthesized PIPKI 661 peptides. Bottom, 
immunoprecipitation was performed using PIPKI 661 overexpressing 
HEK293T lysates supplemented with 5  M indicated PIPKI 661 
peptide. The talin–PIPKI 661 association was analyzed from the 
immunoprecipitates by Western blot as indicated. (C) Direct binding 
curves of synthesized PIPKI 661 peptides with wild-type GST fusion 
talin head domain. 20 nM fluorescein-labeled PIPKI 661 peptides 
were incubated respectively with increased concentration of talin 
head in 0.1% BSA-PBS for 30 min at RT, and then anisotropy values 
were measured and analyzed using SigmaPlot 4.0 from three inde-
pendent experiments. Kd values of wild-type talin head binding to 
each PIPKI 661 peptide are shown as insets.Tyrosine phosphorylation of PIPKI  | Ling et al. 1345
(2003). In addition, we found that the phosphorylated
PIPKI 661 peptides were  20-fold more effective in dis-
placement of His- 1-integrin tail from GST-talin head than
the nonphosphorylated peptide (Fig. 7 B). The analysis
of the integrin competition data revealed that Y644 or
Y649 single- or double-phosphorylated PIPKI 661 peptides
shared similar efficiencies for displacing His- 1-integrin tail
from GST-talin head that is  20-fold higher than the non-
phosphorylated PIPKI 661 peptide (Fig. 7 C). Our current
data suggest that tyrosine-phosphorylated PIPKI 661 could
be a key element in Src-mediated regulation of integrin–
cytoskeleton linkage by competing with  -integrin binding
to the talin FERM domain.
PIPKI 661 binds to talin on an overlapping yet 
distinct site from  -integrin, and K357 and R358 
of talin are responsible for the enhanced binding 
of phosphorylated PIPKI 661
As a key residue for binding to talin (Di Paolo et al., 2002),
W642 of PIPKI 661 aligns with the conserved tryptophan in
the  -integrin tail (Garcia-Alvarez et al., 2003). PIPKI 661
binding to talin through an interaction with W642 would po-
sition Y644 of PIPKI 661 adjacent to K357 and R358 of
talin. To determine if the increased binding affinity of the
phosphorylated PIPKI 661 sequences was due to these two
basic residues, each residue was respectively mutated to gluta-
mine, which is the most conservative mutation that elimi-
nates charge but maintains side chain size. Although both
K357Q and R358Q mutants abolished His- 1-integrin tail
binding, neither mutation had a detectable effect on His-
PIPKI 661 tail binding (Fig. 8 A). The binding curves of
His-PIPKI 661 tail to the wild-type or mutant GST-talin
head showed comparable properties (Fig. 8 B), showing that
both K357Q and R358Q mutants have no effect on talin
binding to PIPKI 661. These data indicate that PIPKI 661
binds to talin on an overlapping yet distinct site compared
with  1-integrin, as concluded by Barsukov et al. (2003).
To assess the impact of PIPKI 661 phosphorylation, the
phosphorylated peptides were used to compete with His-
PIPKI 661 binding to the wild-type or mutant GST-talin
head. As shown in Fig. 8 C, the K357Q mutant retained
high affinity binding for the Y644-phosphorylated peptide,
but lower affinity for the Y649-phosphorylated peptide.
R358Q showed a loss of increased affinity for both Y644-
and Y649-phosphorylated peptides (Fig. 8 C). These results
indicate that both phosphorylated Y644 and Y649 require
R358 for high affinity binding, but phosphorylated Y649
appeared to also require K357. To further examine this hy-
pothesis, we examined the direct binding of fluorescein-
labeled PIPKI 661 peptides with the mutant GST-talin
head. To the K357Q mutated talin head, the binding affin-
ity of Y649-phosphorylated peptide dropped to the compa-
rable level with the nonphosphorylated peptide, whereas
the Y644- and double-phosphorylated peptides maintained
their higher binding affinity (Fig. 8 D). All of the phosphor-
ylated peptides showed decreased binding affinity to the
R358Q mutant compared with the wild-type talin head
(Fig. 8 D), suggesting that R358 is critical for phosphory-
lated PIPKI 661 peptide binding. The anisotropy data re-
vealed that phosphorylation at Y644 or Y649 enhanced the
binding affinity to talin head  15-fold. These results sup-
port the GST pull-down displacement data that K357 is re-
sponsible for tighter binding induced by phosphorylation of
Y649, whereas R358 is critical for tighter binding to talin in-
duced by phosphorylation of both Y644 and Y649. Both
nonphosphorylated and phosphorylated PIPKI 661 pep-
tides showed 3–4 times lower maximum change of anisot-
ropy with the R358Q talin head mutant, consistent with the
recent work by Barsukov et al. (2003). Previous data dem-
onstrate that there is no detectable effect on full-length
PIPKI 661 tail binding to R358Q talin head (Fig. 8, A and
B). This gives rise to the possibility that residues in the last
26 amino acids other than the 15 amino acids in the synthe-
sized PIPKI 661 peptide are involved in the interaction
Figure 7. Phosphorylation of PIPKI 661 disrupts integrin binding 
to talin. (A) 100 nM GST-TaH and 100 nM His- 1-integrin tail 
(His- 1InT) were used for GST pull-down assays with indicated 
amount of His-PIPKI 635 tail (I 635T) or His-I 661T (I 661T). (B) 
The interactions between 100 nM GST-TaH and 100 nM His- 1InT, 
with indicated amounts of synthesized PIPKI 661 peptides, were 
examined by GST pull-down assay and analyzed by Western blot as 
indicated. (C) The displacement curves of synthesized PIPKI 661 
peptides binding to GST-TaH in competition with His- 1InT were 
obtained by GST pull-down and Western blot. Both talin head bands 
and integrin tail bands were quantified by NIH image 1.62, and 
data were plotted by SigmaPlot 4.0 from at least three independent 
experiments.1346 The Journal of Cell Biology | Volume 163, Number 6, 2003
with talin head domain. In addition, the Kd value of non-
phosphorylated PIPKI 661 peptide for the full talin head is
eightfold lower than the reported value for F2F3 domain of
talin (Barsukov et al., 2003), suggesting additional contribu-
tion to the binding energy.
Because dimerization of GST may introduce artifactual
results, we also performed experiments using His-tagged
PIPKI 661 tail and S-tagged recombinant talin head pro-
teins to repeat the representative results. These experiment
showed consistent results with those obtained from the GST
pull-downs (unpublished data).
Tyrosine phosphorylation of  1-integrin tail decreases 
its interaction with talin
The enhanced association of the phosphorylated PIPKI 661
peptides with talin raised the question of whether the  1-
integrin tail may bind to talin with increased affinity when
phosphorylated at the 
780WDT
782 and 
785NPIY
788 motif be-
cause the WDT motif aligns with 
642WVY
644 of PIPKI 661.
To address this question,  1-integrin peptides phosphory-
lated at T783 and/or Y788 were synthesized and used to
compete integrin tail binding to talin. The T783-phosphory-
lated peptide competed with the integrin tail for talin to a
similar extent as the nonphosphorylated peptide, whereas the
Y788-phosphorylated peptide showed lower binding affinity
(Fig. 9). These data indicate that phosphorylation of the
Y788 residue diminished the interaction with GST-talin,
consistent with previous reports (Tapley et al., 1989; Garcia-
Alvarez et al., 2003). These results identify a region on the F3
lobe of talin as a PTB domain that can bind both phosphory-
lated PIPKI 661 or unphosphorylated integrin. The loss of
talin binding to phosphorylated integrin and the enhanced
binding to phosphorylated PIPKI 661 defines a mechanism
by which tyrosine phosphorylation of PIPKI 661 tightly reg-
ulates FA dynamics via an integrin–talin switch.
Discussion
PIPKI 661 is a newly recognized FA-targeting phosphati-
dylinositol phosphate kinase isoform, and was identified as
an important regulator for FA assembly through recruiting
talin to and generating PI4,5P2 at FAs (Di Paolo et al.,
2002; Ling et al., 2002). Previously, the tyrosine phosphory-
lation of PIPKI 661 was shown to regulate its PIP kinase
activity (Ling et al., 2002). The present work demonstrates
that the PIPKI 661–talin interaction and the PIPKI 661
FA targeting require Src-mediated tyrosine phosphorylation
of PIPKI 661 at Y644. This enables PIPKI 661 to produce
PI4,5P2 at FAs, thereby regulating FA assembly. Tyrosine
phosphorylation has been shown to regulate FA turnover;
however, the underlying mechanism is poorly defined. We
speculate that tyrosine phosphorylation of PIPKI 661 pro-
vides a plausible mechanism for the dynamic regulation of
FA organization.
Figure 8. PIPKI 661 and  1-integrin 
bind to distinct sites on the talin head 
region. (A) The interactions between 
50 nM wild-type His-I 661T or His- 1InT 
and 50 nM wild-type (GST-TaH), K357Q 
mutant (GST-TaHK357Q), R358Q mutant 
(GST-TaHR358Q) talin head region, or 
GST alone. (B) Binding curves of His-
I 661T with 20 nM GST-TaH, GST-
TaHK357Q, or GST-TaHR358Q were 
obtained by GST pull-down, Western 
blot, and quantification using NIH image 
1.62, and were plotted using SigmaPlot 
4.0 from at least three independent 
experiments. (C) Interactions between 
20 nM His-I 661T and 20 nM GST-TaH, 
GST-TaHK357Q, or GST-TaHR358Q, 
with or without 500 nM synthesized 
PIPKI 661 peptide as indicated, were 
analyzed by GST pull-down and Western 
blot as indicated. (D) Direct binding 
curves of synthesized PIPKI 661 peptides 
with mutant GST fusion talin head do-
mains were determined by fluorescence 
anisotropy. Kd values of wild-type or mu-
tant talin head binding to each PIPKI 661 
peptide are shown as insets.Tyrosine phosphorylation of PIPKI  | Ling et al. 1347
PIPKI 661 binds talin via the talin FERM domain. The
binding region has been narrowed to the F3 lobe of the
FERM domain, and this lobe has structural homology to
PTB domains (Calderwood et al., 2002; Garcia-Alvarez et
al., 2003). Here, we have shown that phosphorylated
PIPKI 661 peptides bind with high affinity to the F3 lobe,
and K357 and R358 are key residues that bestow increased
affinity to tyrosine-phosphorylated PIPKI 661. To under-
stand the interaction between talin and phosphorylated
PIPKI 661, we structurally modeled the talin F3 lobe with
the dual phosphorylated PIPKI 661 peptide (Fig. 10 A).
This model shows that Y644 is located close to K357 and
R358 of talin and forms a charge–charge interaction with
these residues when phosphorylated. This model is supported
by the observation that mutation of K357 and R358 to gluta-
mine ablated the enhanced binding of the Y644-phosphory-
lated sequences. Unlike the integrin sequence, P646 of
PIPKI 661 creates a turn that also positions Y649 directly
adjacent to K357 of talin. This model is consistent with the
result that the K357Q mutant lost the enhanced binding
to the Y649-phosphorylated PIPKI 661 peptide. Y649 of
PIPKI 661 is in a similar position to Y788 of  1A-integrin,
which was reported to be phosphorylated in Src-transformed
cells (Sakai et al., 2001). However, phosphorylation of Y788
resulted in the loss of integrin binding to the talin head (Fig.
9; Tapley et al., 1989; Garcia-Alvarez et al., 2003). This indi-
cates that P786 of integrin locates integrin Y788 to a position
where the tyrosine-phosphorylated residue may be sterically
hindered from interacting with K357 or R358 of talin.
Our data demonstrate that the FERM domain of talin
acts as a PTB domain by coordinating binding of two differ-
ent tyrosine-phosphorylated sequences in PIPKI 661. This
may be a general function of FERM domains because the
K357 and R358 positions are conserved in other FERM do-
mains including moesin, radixin, ezrin, band 4.1. This sug-
gests that there is structurally conserved binding between
FERM domains and phosphorylated tyrosine residues in se-
quences similar to the PIPKI 661 tail. In addition, the F3
lobe of talin does bind tyrosine-phosphorylated residues in
the context of Y649 in the sequence PLHY, which is similar
to the NPXY sequences that PTB domains normally bind.
This demonstrates that the F3 lobe of talin is a remarkably
flexible PTB domain that can bind two distinct phosphory-
lated tyrosine residues in different sequence contexts.
Current results suggest a mechanism as illustrated in Fig.
10 B, where talin switches between an association with inte-
grin or PIPKI 661 in a dynamic and highly regulated fash-
ion. It is demonstrated here that both FAK and Src are in-
volved in PIPKI 661 tyrosine phosphorylation. Endogenous
PIPKI 661 tyrosine phosphorylation was dependent on ad-
hesion to type I collagen, an  2 1 integrin-dependent signal-
ing process. As a component of this pathway, FAK activates
Src, which then phosphorylates PIPKI 661. In addition,
FAK stimulates an association between Src and PIPKI 661.
This association was also stimulated by adhesion to type I
collagen, indicating that the Src association is physiologically
relevant. The Src–PIPKI 661 association is likely important
for efficient phosphorylation of PIPKI 661. These com-
bined data suggest that  2 1 integrin signaling is one mecha-
nism that leads to phosphorylation of PIPKI 661.
The PIPKI 661-binding site on talin overlaps with the
integrin-binding site, and this competitive interaction is
likely the key for modulation of PIPKI 661 function at
FAs. Current results demonstrate that tyrosine phosphoryla-
tion of PIPKI 661 dramatically enhances talin interaction
and FA targeting, which enable the generation of PI4,5P2 at
FAs to improve the integrin–talin interaction. The enhance-
ment of the integrin–talin association by PI4,5P2 may
ultimately displace PIPKI 661 from talin, resulting in a re-
duction of PI4,5P2. Via this mechanism, PI4,5P2 pro-
duction is self limiting, and in the context of this model
would be highly dynamic. The tyrosine phosphorylation of
PIPKI 661 may also be regulated by PI4,5P2 production
because the kinase-dead enzyme is 20-fold less tyrosine
phosphorylated (Ling et al., 2002). This results in a spatial
and temporal generation of PI4,5P2 that is regulated by inte-
grin binding to ECM, and by Src, FAK, or other signals. Al-
Figure 9. Phosphorylation of  1-integrin tail does not increase 
interaction with talin. Top, sequences and nomenclature of the 
synthesized  1-integrin peptides. Bottom, the interactions between 
100 nM GST-TaH and 100 nM His- 1InT with indicated amount of 
indicated  1-integrin peptides.
Figure 10. Models of talin–PIPKI 661 interaction 
and PIPKI 661-mediated regulation of focal 
adhesion organization. (A) Structure model of talin 
F3 lobe with dual phosphorylated PIPKI 661 peptide 
(green) bound (phosphates are highlighted as red). 
Structure model was generated with the Sybyl mo-
lecular modeling program using the crystal structure 
as guide to dock the phosphorylated peptides, which 
were then energy minimized with the talin F3 lobe. 
(B) Signaling mechanism depicting PIPKI 661 reg-
ulation of FAs and the interplay with  -integrin.1348 The Journal of Cell Biology | Volume 163, Number 6, 2003
though we have not yet identified a kinase that phosphory-
lates Y649, this potential phosphorylation site may be a
link to other signaling pathways for the modulation of
PIPKI 661–talin association and FA dynamics.
FAK and Src family members are important regulators of
FA dynamics (for review see Cary and Guan, 1999; Frame et
al., 2002). Src is required in directed migration stimulated
by growth factors. There is also evidence that adhesion to
the ECM is required for cells to become responsive to
growth factors, and this responsiveness correlates with stim-
ulation of PI4,5P2 production by ECM adhesion (Mc-
Namee et al., 1993). As shown in Fig. 10 B, Src activation
by integrin leads to phosphorylation of PIPKI 661, enhanc-
ing both talin binding and PIP kinase activity (Ling et al.,
2002). Because growth factor receptor and integrin signaling
regulate Src activity, both pathways may lead to phosphory-
lation of PIPKI 661 and regulation of migration.
Recent work has revealed that talin provides the initial con-
nections between the ECM, integrin, and the cytoskeleton
(Jiang et al., 2003). Moreover, talin binding to integrin has
been identified as the final step leading to integrin activation
(Tadokoro et al., 2003). This “inside-out” integrin signaling
modulates both integrin-binding affinity to the ECM and in-
ternal connection to the cytoskeleton via the regulated associa-
tion with talin (Calderwood and Ginsberg, 2003; Calder-
wood et al., 1999, 2002; Ulmer et al., 2003). Currently, the
only known enhancer of the integrin–talin interaction is
PI4,5P2, which induces an  10-fold increase of the binding
affinity (Martel et al., 2001). Regulated production of PI4,5P2
at FAs, via Src-mediated phosphorylation of PIPKI 661, may
be key for modulation of the integrin–talin interaction, and
subsequently, integrin activity and binding affinity for the
ECM. This would provide a mechanism by which migrating
cells can spatially and temporally control adhesion to the
ECM differently at the leading or trailing edge.
Materials and methods
Constructs
Human talin1 head region (1–435) was cloned from HEK293T cells by RT-
PCR using the OneStep RT-PCR kit (QIAGEN) and was subcloned into
pET42. The COOH-terminal truncated or site-directed mutagenesis for the
PIPKI 661 mutants or talin head was performed using PCR-primer overlap
extension with mutagenic primers. PIPKI 661 mutants were then sub-
cloned into pcDNA3.1, and talin head mutants were subcloned into
pET42. His-tagged mouse  1-integrin tail was made following the pub-
lished method (Pfaff et al., 1998), and was subcloned into pET28. The
COOH terminus of PIPKI 635 (439–635), PIPKI 661 (439–661), or the Y
to F mutants of PIPKI 661 were PCR amplified from the corresponding
pcDNA3.1 constructs and subcloned into pET28. PIPKI / 439–635 or PIP-
KI / 439–661 were constructed by fusing residues 1–444 of PIPKI  and
residues 439–635 of PIPKI 635 (PIPKI / 635) or 439–661 of PIPKI 661
(PIPKI / 661) as described in Ling et al. (2002). PIPKI / 636–661 was
constructed by fusion of the COOH-terminal 26 residues of PIPKI 661
(PIPKI / 636–661) to the COOH terminus of PIPKI  as described by Ling
et al. (2002). All mutants were confirmed by DNA sequence analysis. FAK,
FAKY397F, and kinase-dead FAK constructs were gifts from Dr. Patricia J.
Keely (University of Wisconsin, Madison, Madison, WI). The c-Src con-
struct was provided by Dr. Alan C. Rapraeger (University of Wisconsin,
Madison, Madison, WI).
Cell cultures and transfection
HEK293T cells, NRK cells, and A431 cells were cultured using DME sup-
plemented with 10% FBS. FAK
 / , FAK
 / , SFY
 / , and Src
 /  cells, pro-
vided by Dr. Patricia J. Keely, were maintained in DME supplemented with
10% FBS. NRK cells were plated on glass coverslips and transfected us-
ing FuGENE™ 6 following the manufacturer’s instructions. 0.5   10
6
HEK293T cells were transfected by calcium phosphate using 2  g PIPKI 
expression vectors together with 4  g empty pcDNA3 vector, 2  g empty
pcDNA3 vector plus 2  g wild-type or mutant FAK, 2  g empty pcDNA3
vector plus 2  g c-Src, or 2  g wild-type or mutant FAK plus 2  g c-Src.
SFY
 /  and Src
 /  cells were plated on glass coverslips for 16 h and then
used for immunofluorescence.
Antibodies
Anti-talin and anti-Flag (M2) antibodies were purchased from Sigma-
Aldrich. Monoclonal mouse anti-PY (4G10), anti-Src (EC10), and anti-FAK
(4.47) were obtained from Upstate Biotechnology. Anti-HA and anti-c-Myc
antibodies were purchased from Covance. HRP-conjugated anti-GST anti-
body was purchased from Amersham Biosciences. Anti-His and HRP-con-
jugated anti-T7 antibodies were purchased from Invitrogen. Polyclonal
PIPKI  anti-serum was generated and purified as described previously (Ling
et al., 2002). Secondary antibodies were obtained from Jackson Immuno-
Research Laboratories.
Protein expression and purification in Escherichia coli
pET28 or pET42 constructs were transformed in BL21(DE3) (Novagen).
Proteins were expressed and purified using His resin following the manu-
facturer’s instructions (Novagen).
In vitro Src kinase assay and phosphopeptide mapping
Primary chicken embryo cells were prepared as described previously (Rey-
nolds et al., 1989). Exogenous c-SrcY527F was expressed using the RCAS
B replication competent avian retroviral vector as described previously
(Schaller et al., 1999). Cells were transfected with LipofectAMINE™ (Life
Technologies) and LipofectAMINE™ Plus (Life Technologies) according to
the manufacturer’s instructions. Approximately 7–9 d after transfection,
cells were lysed in RIPA buffer.
Overexpressed c-Src was immunoprecipitated from  1 mg chicken em-
bryo cell lysates using EC10 and protein A–Sepharose (Amersham Bio-
sciences) for 1 h at 4 C. Immune complexes were washed twice with RIPA
buffer, twice with TBS, and twice with kinase reaction buffer (20 mM Pipes,
pH 7.2, 5 mM MnCl2, and 5 mM MgCl2). The immune complexes were in-
cubated with 4  g recombinant substrates for various times at RT in kinase
reaction buffer containing 35  M ATP including 10  Ci  [
32P]ATP (6,000
Ci mmol
 1; PerkinElmer), and were then terminated by adding sample
buffer. Samples were resolved by SDS-PAGE, stained with SYPRO
® Orange
(Molecular Probes, Inc.), and analyzed after drying for fluorescence and by
phosphorimaging, using a PhosphorImager
® (Storm
®; Molecular Dynamics).
4  g recombinant substrates were tyrosine phosphorylated using
c-SrcY527F in vitro as described above. The samples were resolved by
SDS-PAGE, transferred to nitrocellulose membranes, and visualized by au-
toradiography. The 
32P-labeled substrate bands were excised and digested
twice with 10  g trypsin in 200  l 0.05 M ammonium bicarbonate for 2 h
each time at 37 C. The trypsinized membrane bands were oxidized on ice
using 75  l performic acid for 1 h and lyophilized as described by Boyle et
al. (1991). Analysis by two-dimensional phosphopeptide mapping on thin-
layer cellulose plates was performed using the Hunter thin-layer peptide
mapping system (CBS Scientific) with methods described by Boyle et al.
(1991). Electrophoretic resolution was performed in pH 1.9 buffer (2.2%
formic acid, 7.8% acetic acid) for 30 min at 1,000 V. Then, ascending
chromatography was performed for 3–4 h in phosphochromo buffer
(37.5%  n-butanol, 25% pyridine, and 7.5% acetic acid in water). The
plates were dried and visualized by autoradiography at  70 C for 7 d with
intensifying screens.
Immunoprecipitation and immunoblotting
Cells were harvested and lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% NP-40, 5.0 mM NaF, 2 mM Na3VO4, 4 mM Na2P2O7, 1 mM EDTA,
and 1 mM PMSF. 1–2-mg cell lysates were incubated with protein A–Seph-
arose and 5  g anti-HA, anti-flag, anti-talin, or 10  g purified anti-PIPKI 
antibody as indicated at 4 C overnight. The immunocomplexes were sepa-
rated by SDS-PAGE, and analyzed as indicated.
Immunoblotting data were scanned, and the gray scale of each band
was determined by NIH image 1.62 and then plotted using SigmaPlot 4.0
as described before (Ling et al., 2002).
Immunofluorescence and confocal microscopy
Immunofluorescence was performed as described previously (Ling et al.,
2002). In brief, NRK cells 16 h after transfection, SFY
 / , or Src
 /  cells
were washed with PBS at 37 C, fixed by 4% PFA at RT for 10 min, and per-
meabilized by 0.2% Triton X-100 in PBS at RT for 10 min. Then, cells wereTyrosine phosphorylation of PIPKI  | Ling et al. 1349
blocked by 3% BSA in PBS at RT for 30 min, incubated with the primary
antibody for 1 h at 37 C, washed with 0.1% Triton X-100 in PBS, incu-
bated with fluorescence-labeled secondary antibody at RT for 30 min, and
then washed with 0.1% Triton X-100 in PBS. Cells were maintained and
examined using a 60  Plan oil immersion lens on a confocal laser-scan-
ning microscope (model MR-1000; Bio-Rad Laboratories) mounted trans-
versely to an inverted microscope (Diaphot 200, Nikon; W.M. Keck Labo-
ratory for Biological Imaging, Madison, WI). Images were processed as
described previously (Ling et al., 2002) using Photoshop
® 7.0.
Peptide synthesis and GST pull-down assay
Phosphorylated or nonphosphorylated peptides relevant to PIPKI 661,
named as PN (CDERSWVYSPLHYSAR), pY644 (CDERSWVpYSPLHYSAR),
pY649 (CDERSWVYSPLHpYSAR), and pY644/649 (CDERSWVpYSPLH-
pYSAR), were synthesized and purified by HPLC at  95% purity (Invitro-
gen). Fluorescein-labeled tyrosine-phosphorylated or nonphosphorylated
PIPKI 661 peptides (labeled at the NH2 terminus) and peptides corre-
sponding to  1-integrin tail, named as  1InPN (CMNAKWDTGEN-
PIYKSA),   1InpT (CMNAKWDpTGENPIYKSA),  1InpY (CMNAKWDT-
GENPIpYKSA), and  1InpTpY (CMNAKWDpTGENPIpYKSA), were
synthesized and purified by HPLC at  97% purity in the Peptide Synthesis
Facility at the University of Wisconsin Biotechnology Center (Madison,
WI). Purities, sequences, and correct phosphorylation of all synthesized
peptides were confirmed by the Mass Spectrometry/Bioanalytical Facility
at the University of Wisconsin (Madison, WI).
Purified GST-talin head proteins were incubated with PIPKI 661 tails
and/or  1-integrin tail, with or without synthesized PIPKI 661 or  1-inte-
grin peptides, together with glutathione Sepharose 4 Fast Flow (Amersham
Biosciences) in 500  l buffer B (PBS, 0.2% NP-40, and 2 mM DTT) for 4 h
at 4 C. The beads were washed with 1 ml buffer B five times and analyzed
by Western blot.
Fluorescence polarization assay
20 nM of each fluorescein-labeled PIPKI 661 peptide was incubated with-
out or with different titration of wild-type, K357Q, or R358Q mutated
GST-talin head in PBS containing 0.1% BSA for 30 min at RT. Then the
anisotropy value of each sample was determined using a photo counting
spectroflurometer (SLM 8000C
®; SLM Instruments) operating with an SLM
8100 hardware/software upgrade (Spectronic Instruments) at 25 C. Anisot-
ropy value of peptide alone was abstracted from each of the relevant val-
ues of peptide bound to talin head. Data were analyzed and binding
curves were plotted using SigmaPlot 4.0.
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